slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 7,381-7,410
Pages 395
Rows per page 30
Slide function
7,381-7,410 of 11,828
04
The slide uses a dual-track timeline (Cell Therapy and Drug Discovery) to show company evolution.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
07
The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
08
The chart shows a cumulative growth trend of partner milestones over time, with logos placed in vertical columns representing years.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
10
The slide uses two donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
The diagram uses concentric circles to represent clinical phases and color-coded dots for cell approaches (Allogeneic vs Autologous).MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
The slide uses a Vitruvian-man style silhouette to represent the breadth of therapeutic applications.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
The slide uses a process diagram to illustrate the workflow context for the company's technology.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Loop · Why Now1 hit
08
Includes a process diagram for iPSC generation and two charts: a survival curve and a hazard ratio bar chart.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
Study identifier NST002, 15 patients, open-label, intermediate formulation.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
17
The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
19
The chart visualizes the reduction in point loss, highlighting the efficacy of PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
20
The slide uses a human silhouette to categorize ALS symptoms into four domains, then presents bar charts for each domain comparing treatment vs placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
21
The chart highlights a 17.2% attenuation in the decline of SVC scores for the PrimeC group compared to placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
25
The slide presents clinical biomarker data comparing control vs AD groups across 6 different markers, using Mann-Whitney U tests for significance.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
31
The chart shows a clear divergence between the treatment and placebo arms over time, with a 29.2% difference at the 180-day mark.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
32
The chart shows a divergence in SVC decline between the treatment and placebo groups over time.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a chronological structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 across different patient cohorts.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a chronological structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
19
Slide presents two distinct clinical data visualizations: a PK line chart and a waterfall plot for mutation clearance.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Swimmer plot visualization of clinical trial patient outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Includes before/after MRI scans for two specific patient cases.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes a summary table of ORR and best response, and a waterfall plot showing individual patient tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes clinical trial data (ARROS-1 Phase 1) with specific patient subgroup outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The chart shows pharmacokinetic data (NVL-520 concentration over time) compared against target efficacy thresholds for different ROS1 variants.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit